Sandvik: Interim report second quarter 2025
Order intake SEK 32,206 million (32,354)
Order intake, at fixed exchange rates, increased by 10%
Revenues SEK 29,700 million (31,419)
Revenue growth, at fixed exchange rates increased by 4%
Adjusted EBITA SEK 5,629 million (6,149)
Adjusted EBITA margin 19.0% (19.6)
Adjusted EBIT SEK 5,194 million (5,688)
Adjusted EBIT margin 17.5% (18.1)
Adjusted profit before tax SEK 4,855 million (5,124)
Profit for the period SEK 3,216 million (3,462)
Adjusted profit for the period SEK 3,713 million (3,897)
Earnings per share, diluted SEK 2.56 (2.76)
Adjusted earnings per share, diluted SEK 2.96 (3.10)
Free operating cash flow SEK 5,090 million (4,198)
Additional information may be obtained from Sandvik Investor Relations, phone +46 70 782 63 74 (Louise Tjeder).
A webcast and conference call will be held on July 16, 2025, at 1:00 PM CEST. Information is available at home.sandvik/investors
Stockholm, July 16, 2025Sandvik Aktiebolag (publ)
Stefan WidingPresident and CEO
This information is information that Sandvik AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at about 11:30 AM CEST on July 16, 2025.
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/sandvik/r/interim-report-second-quarter-2025,c4207760
The following files are available for download:
https://mb.cision.com/Main/208/4207760/3582224.pdf
Interim Report Q2 2025
View original content:https://www.prnewswire.com/news-releases/sandvik-interim-report-second-quarter-2025-302506652.html
SOURCE Sandvik
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends, market drivers, competitive landscape, and strategies for growth and investment in the NTM market. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast" report has been added to report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems.). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these Highlights Report deliverables include a Pdf report and an Excel-based forecast model Forecast includes the 7 major markets (7MM) Forecast covers the period 2023-2033 Scope Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms. Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period. Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Key Topics Covered: 1. Preface1.1. Contents1.2. Abbreviations1.3. Related Reports2. Executive Summary3. Disease Overview3.1. Overview of NTM3.2. NTM Market SWOT Analysis3.3. Classification of NTM3.4. NTM Risk Factors4. Epidemiology4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-334.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-334.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 20234.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM5. Current Treatment Options5.1. PNTM Diagnostic Paradigm5.2. Treatment Paradigm5.3. Current Treatment Options6. Unmet Needs and Opportunities6.1. Unmet Needs in NTM6.2. New Therapeutic Options with Improved Efficacy6.3. Improved Diagnostic Methods6.4. Improved Clinical Trials7. R&D Strategies7.1. Trends in Clinical Trial Design in NTM7.2. Trends in Deal-Making in NTM8. Pipeline Assessment8.1. NTM Pipeline Overview8.2. Late-Stage Pipeline Products for NTM8.3. NTM Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. NTM Market Forecast9.2. PNTM Market Forecast9.3. DNTM Market Forecast9.4. Market Drivers and Barriers10. Appendix Competitive Landscape Janssen Novartis AG Meiji Seika Pharma Co Ltd Insmed Inc Daiichi Sankyo Co Ltd MannKind Corp Paratek Pharmaecuticals Inc Nobelpharma Co Ltd GlaxoSmithKline AG Pfizer For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
H.B. Fuller Announces Quarterly Dividend
ST. PAUL, Minn., July 17, 2025--(BUSINESS WIRE)--H.B. Fuller Company (NYSE: FUL) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.2350 per share of common stock, payable on August 14, 2025 to shareholders of record at the close of business on July 31, 2025. H.B. Fuller has paid quarterly cash dividends on its common stock for 57 consecutive years. About H.B. Fuller Company: As the largest pureplay adhesives company in the world, H.B. Fuller's (NYSE: FUL) innovative, functional coatings, adhesives and sealants enhance the quality, safety and performance of products people use every day. Founded in 1887, with 2024 revenue of $3.6 billion, our mission to Connect What Matters is brought to life by more than 7,500 global team members who collaborate with customers across more than 30 market segments in over 140 countries to develop highly specified solutions that enable customers to bring world-changing innovations to their end markets. Learn more at View source version on Contacts Worldwide Headquarters1200 Willow Lake BoulevardSt. Paul, Minnesota 55110-5101 Steven BrazonesInvestor Relations651-236-5060 Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
EasyJet warns on profit hit from French air strike and fuel costs
STORY: EasyJet forecast an almost $33.5 million hit to annual profit on Thursday (July 17). It said this was due to a strike by French air traffic controllers earlier this month and rising fuel costs. Sending the airline's shares down as much as 8% in early trade. The low-cost carrier said is still expects 'good profit growth' for the year ending September. EasyJet reported that pretax Q3 profit rose around $67 million to $383 million, matching expectations. :: July 4, 2025 Its CEO in a statement voiced unhappiness with the strike actions which 'presented unacceptable challenges'. Some analysts said the carrier cut forecasts for the year based on Thursday's results. Demand has remained strong for easyJet's budget-friendly flights and holiday packages. But travelers overall are taking longer to book tickets amid worsening macroeconomic sentiment. Its CEO said that this trend "could have something to do with hot weather". Positing that travelers are waiting to see how soaring heatwaves in Europe play out.
